GKS procedures were performed at Roger Salengro Hospital in Lille, France, in patients with non-tumor-related TN. Two patients with multiple sclerosis were excluded from the present study. Thus, the outcomes of single-session GKS for 76 patients with medically intractable idiopathic TN were available for analysis.
O nce the diagnosis of essential TN is made, medical therapy becomes the initial approach in most cases. However, medical therapy in many patients is either unsuccessful or they are unable to tolerate it, and these patients eventually require surgical intervention. In the past, surgery typically involved MVD or one of several percutaneous ablative procedures.
14 Although often associated with initial pain relief, all those surgical procedures have variable but definitive rates of recurrence and morbidity. The use of SRS has been advocated as a minimally invasive alternative surgical approach for treating TN. Stereotactic irradiation of the trigeminal ganglion was first reported by Leksell. 10 More recently, several authors have reported their initial results with radiosurgery in which high-resolution image guidance was used. [7] [8] [9] 15, 19, 21, 23, 24, 28, 29 Such data have helped to establish the accuracy of radiosurgical targeting and the initial safety of the procedure, as well as providing dose-response information. In the present study, we reviewed our initial experience with GKS in the treatment of TN to identify factors associated with success or complications.
Abbreviations used in this paper: BNI = Barrow Neurological Institute; GKS = Gamma Knife surgery; MVD = microvascular decompression; SRS = stereotactic radiosurgery; TN = trigeminal neuralgia. tailed in Table 1 . All patients reported episodic shocklike pain involving 1 or more divisions of the trigeminal nerve. Facial pain was experienced on the right side in 36 patients (47.4%) and on the left side in 40 patients (52.6%). Twelve patients (15.8%) experienced pain in V1, 25 (32.9%) in V2, 13 (17.1%) in V3, 23 (30.3%) in V1 and V2, 2 (2.6%) in V2 and V3, and 1 (1.3%) in all 3 trigeminal nerve divisions.
Surgery had been previously performed in 30 (39.5%) of the 76 patients. Among these patients there was a mean of 1.7 operations including radiofrequency rhizotomy (20 patients), balloon microcompression (9 patients), MVD (4 patients), and glycerol rhizotomy (1 patient). In the remaining 46 patients (60.5%), Leksell GKS was the first surgical procedure performed.
Radiation Dosimetry
The procedure on the day of GKS treatment began with application of the Leksell stereotactic frame (Elekta Instruments AB) to the patient's head after induction of local anesthesia. After the frame fixation, MR and CT imaging were used for dose planning with Leksell GammaPlan software (Elekta Instruments AB). The MR images were calibrated before examination and verified by comparison with the CT images for each patient to minimize magnetic distortion errors. One single exposure with the 4-mm collimator was placed on the anterior part of the cisternal portion of the trigeminal nerve (Fig.  1) . The median dose delivered at the maximum was 85.1 Gy (range 75-90 Gy). The output factor for dose calculation at this time was 0.80. The maximal dose was determined by monitoring the measured dose to the brainstem (maximum of 12 Gy at the first 10 mm 3 of the brainstem). Gamma Knife surgery (Model 4C, Elekta Instruments AB) treatment proceeded according to routines of the department, and the patients were discharged within 24 hours after GKS.
Follow-Up Procedures
Face-to-face and/or telephone-administered questionnaires were used to assess the level of pain control in each patient, as well as time until pain recurrence and treatment-related side effects. Patients were asked to document their level of pain before and after treatment. More specifically, patients were asked about their "best pain score" attained 3 months after treatment, and their current level of pain control using the BNI pain intensity scale 25 as follows: I, no pain and no pain medication used; II, occasional pain not requiring medication; IIIa, no pain and pain medication used; IIIb, some pain adequately controlled with medication; IV, some pain not adequately controlled with medication; or V, severe pain without relief with medication. We considered the patients' "best" pain scores to analyze initial treatment responses, whereas current pain scores reflected the patients' pain scores at the last follow-up, which was also used to evaluate the long-term treatment effect. If patients experienced pain relief after GKS, they were asked to identify the approximate time-to-pain relief, using 1 of the following 6 categories: 1, pain relief within 24 hours or less; 2, pain relief within 1 week; 3, pain relief within 2-4 weeks; 4, pain relief between 1 and 3 months; 5, pain relief within 3-6 months; or 6, pain relief after 6 months. A score of 7 reflected a patient with no response to treatment. At the time of the last follow-up, each patient was asked to characterize his or her use of pain medication compared with their preprocedure use according to 1 of the following categories: 1, no medication required; 2, 75% reduction in medication required; 3, 50% reduction in medication required; 4, 25% reduction in medication required; or 5, same use of medication required or more pain medication required.
Patients were asked to describe all side effects and complications experienced with treatment. The complication of facial numbness was further characterized using the BNI facial numbness scale 25 with scores from I to IV as follows: I, no facial numbness; II, some facial numbness/not bothersome; III, some facial numbness/somewhat bothersome; or IV, facial numbness/very bothersome.
Statistical Analysis
Data analysis was performed using Epi Info version 6.02 and MedCalc version 9.3.9.0. To evaluate the effectiveness of the treatment over time, we calculated the duration of complete pain relief by using the Kaplan-Meier method. 5 A univariate analysis of the following variables was performed with regard to facial pain outcome and postoperative trigeminal dysfunction: sex, age, duration of symptoms, prior trigeminal deficits (yes/no), length of the nerve, previous surgery (yes/no), and radiation dose (< 85 or ≥ 85 Gy). In addition, facial pain outcome was analyzed to determine whether there was any correlation with the development of postoperative trigeminal dysfunction. Parametric variables were compared by means of the Student t-test, and nonparametric variables were compared by means of the chi-square test. The same factors were used to perform a stepwise multivariate analysis, which was performed using the Cox proportional hazards model. In all cases, statistical significance was established at a probability value < 0.05.
Results

Facial Pain Outcomes
Before treatment, 61 patients reported a pain score of IV and 15 patients reported a score of V. Treatment results are shown in Table 2 . A pain score of I, II, and IIIa were defined as complete pain relief or excellent outcome. A pain score of IIIb, IV, and V were defined as treatment failure or poor outcome. Considering the best pain score, 75 patients (98.7%) reached initial complete pain relief at a mean of 2.6 months after treatment.
Sixty-five patients (86.8%) responded to GKS within 4 weeks of the procedure. Nine patients responded to GKS in 1-3 months. At the initial follow-up assessment (3 months after treatment), complete pain relief was obtained in 75 patients (98.7%), and treatment failure occurred in 1 patient (1.3%). At the last follow-up evaluation (mean 20.3 months after GKS), 54 patients (71.1%) had excellent outcome, 36 of whom (66.6%) did not require medication, 12 (22.2%) with a 75% reduction in the medication required, and 6 (11.1%) with a 50% reduction in medication required. Twenty-one patients (26.6%) experienced recurrence of pain after initially achieving pain relief between 2 and 42 months (mean 13.6 months) after GKS.
The duration of pain relief after treatment was also analyzed in all patients using the Kaplan-Meier method. The results are shown in Figs. 2 and 3. The duration of pain relief was considered to be the time between the treatment and pain recurrence, if any. Patients who did not respond to GKS were recorded as having a pain relief duration of 0 months. Therefore, the first part of the Kaplan-Meier curve, at Time 0, shows the percentage of patients who did not respond to the treatment at all. Complete pain relief was achieved and maintained in 92.1% (± 3.0%) of patients for 6 months, 83.1% (± 4.4%) for 1 year, 70.9% (± 6.0%) for 2 years, and 62.5% (± 7.8%) for 3 years.
The univariate analysis of the patients' characteristics and treatment parameters found only 1 statistically significant factor related to achieving and maintaining complete pain relief: no previous surgery (p = 0.002). The multivariate analysis also demonstrated that patients with TN who had not undergone previous surgery had better outcomes after radiosurgery (relative ratio 4.24, 95% confidence interval 1.03-13.3; p = 0.014). Age, pain duration, postoperative trigeminal dysfunction, length of the nerve, sex, and radiation dose were not associated with facial pain outcomes.
Complications of Radiosurgery
Twenty-one patients had preexisting facial numbness before treatment. New or worsened persistent trigeminal dysfunction developed after GKS in 16 patients, 8 of whom described some facial numbness/not bothersome, and 8 reported some facial numbness/somewhat bothersome. Six patients with facial numbness/not bothersome developed worsened trigeminal dysfunction (facial numbness/somewhat bothersome). Two patients with no facial numbness developed facial numbness/somewhat bothersome (Table 3) . Three patients had corneal numbness before treatment, and one patient developed corneal numbness after treatment. None of the patients developed facial numbness/very bothersome or dysesthesias, neuropathic pain, dry eye, keratitis, or jaw weakness after procedure.
Previous surgery for TN (p = 0.44), prior trigeminal deficits (p = 0.71), radiation dose (p = 0.71), and length of the nerve (p = 0.52) did not correlate with new or worsened post-GKS trigeminal deficits as shown by the univariate analysis.
Discussion
The number of patients with TN who undergo SRS has increased dramatically over the past several years. The first results in the early 1990s regarding GKS treatment for TN were very promising, with high rates of pain cessation and very little hyperesthesia. 6, 22, 23, 30 Although 63 of the first 762 patients (8%) who underwent radiosurgery at the Karolinska Institute between 1968 and 1982 suffered from TN, the inability to visualize the trigeminal system clearly at the time limited the usefulness of this technique. 11 With the advent of CT and MR imaging, however, physicians can now obtain clear images of the trigeminal root to plan the radiosurgery dose. Rand et al. 21 reported on 12 patients with TN who underwent radiosurgery during which the maximum radiation doses ranged from 57.1 to 76 Gy. Seven of these patients experienced improvements in their facial pain, 6 of whom attained total pain relief. Encouraged by these early results, Kondziolka and colleagues 8 conducted a prospective multi-institutional dose-escalation trial to further characterize the results of this procedure. Overall, 29 (58%) of 50 patients attained pain cessation and another 18 patients (36%) experienced a > 50% reduction in pain. During a mean follow-up period of 18 months, 3 patients (6%) experienced recurrent pain and 3 others had facial paresthesias. Importantly, patients in whom the maximum radiation dose was 70 Gy or greater had a significantly greater chance of complete pain relief compared with patients in whom the dose was < 70 Gy.
After that study, some studies reported a latency interval to pain relief of ~ 1-2 months. 6, 9, 23, 29 In the present analysis, we found that 86.8% of the patients responded to treatment within 4 weeks. The best pain score was achieved at a mean time of 2.6 months, with 75 patients reaching this level of relief within 6 months.
In the current patient series, the last follow-up showed that 54 (71%) of the 76 patients were free of pain at a mean period of 20.3 months. Complete pain relief was attained in 83.1 and 62.5% of the patients within 1 and 3 years after radiosurgery, respectively. Patients who had not previously undergone surgery had significantly better outcomes than patients who had undergone prior operations (Fig. 3) . Table 4 provides a comparison of our results and those of other published studies on radiosurgery for idiopathic TN. In such patient series, factors that have been associated with improved results are normal preoperative facial sensation, 18 higher radiation doses, 8, 18, 22 absence of prior surgery, 2, 12, 15, 19, 29 and postoperative trigeminal dysfunction. 17, 19, 20 Consequently, our results are quite similar to those earlier reports and emphasize that, similar to other operations for TN, radiosurgery appears to be more effective when used as a primary surgery than when used in patients who experience recurrent pain after undergoing operations with poor outcome.
However, the reported results of radiosurgery are not as good as those observed after MVD, as Barker et al. 1 report that complete pain relief was maintained in 70% of patients at 10 years after MVD. Based on the review of literature, we continue to advocate that MVD is appropriate for younger patients with TN because of the potential for a longer duration of pain relief. Nevertheless, the potential risks of MVD make it unsuitable for some patients. In addition, the benefits of MVD are reduced in cases in which it is used a second time, or for recurrent TN. 20 The optimal radiation dose in SRS treatment of TN remains a controversial issue. Our treatment procedure was mainly inspired by the method developed by Régis et al., 22 which comprises a more distal target and higher radiation dose than other Gamma Knife users. 15 In the present study the high maximal dose (75-90 Gy, median 85.1 Gy) was used in all patients. Significant variations exist in the prescribed radiation doses in previously published series. 2, 8, 15, 26, 27 It must be emphasized that the actual delivered dose might be different from the prescribed maximal dose from one Gamma Knife unit to another due to variations in the output factor for the 4-mm collimator (0.8-0.85), depending on the institution and the medical physics' techniques used to measure the output factors. 16 In addition, several other parameters such as advanced patient age, the presence of concomitant vasculopathy, systemic disease such as multiple sclerosis, a small trigeminal cistern, and/or a history of previous radiosurgical treatment may lead to the use of a lower radiation dose. 4 Massager et al. 17 have emphasized the fact that radiobiological effects of GKS may be related to the energy delivered to the trigeminal nerve root volume, rather than the maximal radiation dose delivered. These authors found that a 90-Gy dose can be used when targeting anteriorly to the retrogasserian part of the trigeminal nerve, although they recommended not using beam channel blocking when possible.
One of the frequently cited advantages of radiosurgery for TN, compared with percutaneous surgical techniques, is the low risk of new trigeminal dysfunction with similar efficacy. Paresthesia or numbness of variable degrees is observed in 20-70% of patients after percutaneous thermorhizotomy, glycerol rhizotomy, or balloon nerve compression. 13 The incidence of such complications after radiosurgery has been reported to be between 0 and 37% 2, 6, 15, 18, 19, 22, 27, 29 (Table 4 ). In our study, 16 patients (21%) developed new or worsened facial numbness, 8 of whom (10%) reported the numbness to be somewhat bothersome. None of the patients experienced dysesthesias or neuropathic pain. We found no correlation between previous surgery for TN, prior trigeminal deficits, radiation dose, or length of the nerve with new or worsened post-GKS trigeminal deficits. However, several authors have demonstrated that the incidence of post-SRS facial numbness is associated with the prescribed maximal radiation dose, the actual delivered radiation dose, the exact anatomy of the target, a history of previous surgery for TN, and the presence of concomitant vasculopathy or other systemic diseases. 17, 26 Some authors have advocated percutaneous balloon nerve compression as advantageous for the management of V1 TN because of the lower risk of postoperative corneal analgesia. 3, 13 However, in the present study no patient developed this complication, and this result is also demonstrated in most studies on the efficacy of GKS for TN. 13 Moreover, the reduced rate of facial sensory deficits or symptoms indicates that effects on nerve tissue may be less pronounced than after other ablative procedures. Thus, the mechanistic effect of GKS is likely to be a combination of both histological and electrophysiological responses. 15 
Conclusions
Overall, our method of stereotactic GKS provided safe and effective management of medically intractable idiopathic TN. Patients who had not undergone previous surgery on the trigeminal nerve appeared to respond bet- ter to GKS than patients who had undergone previous surgery. According to the given published data, MVD should continue to be the procedure of choice for medically fit patients who suffer from idiopathic TN.
